Search

everythinglearnresearchcommunity

for

Search:↓

Removing UBE2N from skin cells causes inflammation and immune response, which can be lessened with specific inhibitors.

Blocking the HEDGEHOG-GLI1 pathway can reduce keloid growth and may be a potential treatment.

BMS-470539 reduces skin fibrosis and inflammation.

A gene called Gk5 controls lipid production in the skin and affects hair growth.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

WIF1 helps keep skin stem cells inactive to prevent excessive cell growth.

Antizyme slows skin tumor growth by reducing cell growth in mice.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.

Oral difelikefalin significantly reduces itch in notalgia paresthetica.

Some patients on immune therapy for melanoma may develop scarring hair loss, but cancer treatment remains effective.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Teicoplanin may help treat hair loss by reducing androgen receptors and boosting hair cell growth.

Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.

ICP5249 helps hair grow by activating a specific cell pathway.

Trichostatin A helps restore hair-growing ability in skin cells used for hair regeneration.

Vitexin Compound 1 may help reduce skin aging caused by UVA light.

Ent-kaurane-type diterpenoids from Isodonis Herba may promote hair growth by boosting cell proliferation.

Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.

Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.